KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Long-Term Investments (2016 - 2025)

Jazz Pharmaceuticals has reported Long-Term Investments over the past 11 years, most recently at $1.0 billion for Q4 2025.

  • Quarterly results put Long-Term Investments at $1.0 billion for Q4 2025, up 81.03% from a year ago — trailing twelve months through Dec 2025 was $1.0 billion (up 81.03% YoY), and the annual figure for FY2025 was $1.0 billion, up 81.03%.
  • Long-Term Investments for Q4 2025 was $1.0 billion at Jazz Pharmaceuticals, up from $720.0 million in the prior quarter.
  • Over the last five years, Long-Term Investments for JAZZ hit a ceiling of $1.0 billion in Q4 2025 and a floor of $60.0 million in Q2 2022.
  • Median Long-Term Investments over the past 5 years was $387.5 million (2024), compared with a mean of $417.5 million.
  • Biggest five-year swings in Long-Term Investments: surged 681.25% in 2024 and later decreased 23.2% in 2025.
  • Jazz Pharmaceuticals' Long-Term Investments stood at $335.0 million in 2021, then crashed by 82.09% to $60.0 million in 2022, then skyrocketed by 100.0% to $120.0 million in 2023, then soared by 383.33% to $580.0 million in 2024, then skyrocketed by 81.03% to $1.0 billion in 2025.
  • The last three reported values for Long-Term Investments were $1.0 billion (Q4 2025), $720.0 million (Q3 2025), and $480.0 million (Q2 2025) per Business Quant data.